Naming Convention, Interchangeability, and Patient Interest in Biosimilars

Although biosimilars may offer cost savings over their comparable biologics, use of biosimilars in the United States remains relatively low. This study investigates two barriers to uptake of biosimilars in the United States. First, the U.S. Food and Drug Administration requires that four-letter suff...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Spectr
Päätekijät: Socal, Mariana P., Garrett, Jace B., Tayler, William B., Bai, Ge, Anderson, Gerard F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Diabetes Association 2020
Aiheet:
Feature Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7428664/
https://ncbi.nlm.nih.gov/pubmed/32848349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/ds19-0065
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia